New sleep drug aims to help Parkinson's patients get a good Night's rest

NCT ID NCT07714772

Not yet recruiting Symptom relief Sponsor: Second Affiliated Hospital of Soochow University Source: ClinicalTrials.gov ↗

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This study tests whether dimdazenil, a sleep medication, can safely improve sleep in people with Parkinson's disease who also have insomnia. Researchers will measure sleep changes using overnight brain-wave recordings. The trial involves 50 adults with mild-to-moderate Parkinson's and poor sleep.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dimdazenil, a GABAA receptor partial agonist
What this could lead to: If successful, dimdazenil could offer a new treatment option for insomnia in Parkinson's disease, potentially improving sleep quality and overall well-being.
What could go wrong: This is a small, early-stage study with only 50 participants, so results may not apply to everyone. The drug may cause side effects or fail to improve sleep significantly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INSOMNIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

insomnia Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INSOMNIA PARKINSON'S DISEASE (PD)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.